AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2691069 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar CR (controlled‐release levodopa plus benserazide)
Number of subjects: 103
Study 2691069 — intervention group
Group type: COMPARATOR
Intervention: Standard Madopar
Number of subjects: 103
Study 4557029 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0
Study 4557029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 28730741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational feedback from coach
Number of subjects: 120
Study 28730741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational feedback from athlete leader
Number of subjects: 120
Study 28730741 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational feedback from both coach and athlete leader
Number of subjects: 120
Study 28730741 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motivational feedback)
Number of subjects: 120
Study 26814715 — intervention group
Group type: EXPERIMENTAL
Intervention: SeCTG + TT
Number of subjects: 50
Study 26814715 — intervention group
Group type: COMPARATOR
Intervention: SeCTG + CAF
Number of subjects: 50
Study 24729145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 26
Study 24729145 — intervention group
Group type: COMPARATOR
Intervention: Vicryl sutures
Number of subjects: 26
Study 24729145 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 23578860 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 120
Study 23578860 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 120
Study 20179125 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing
Number of subjects: 314
Study 20179125 — intervention group
Group type: COMPARATOR
Intervention: Repeat smear test at six months
Number of subjects: 314
Study 20179125 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed choice of either test supported by a decision aid
Number of subjects: 314
Study 18450843 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse‐led disease management programme
Number of subjects: 1163
Study 18450843 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard general practice care)
Number of subjects: 1163
Study 16600924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 50 mug/d plus 500 mg Ca/d
Number of subjects: 123
Study 16600924 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 500 mg Ca/d
Number of subjects: 123
Study 16600924 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study 14750575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment starting at 40 mg per day, tapering over 4 months
Number of subjects: 75
Study 14750575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11203411 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (250 pg/12 hours) for 3 months
Number of subjects: 94
Study 11203411 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 94
Study 8725679 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 430
Study 8725679 — intervention group
Group type: COMPARATOR
Intervention: Missed dialysis treatments
Number of subjects: 430
Study 1564415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cervical adjustments (C6‐C7)
Number of subjects: 0
Study 1564415 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper cervical adjustments (C2‐C3)
Number of subjects: 0
Study 3909958 — intervention group
Group type: EXPERIMENTAL
Intervention: ACV-recombinant human alpha 2 IFN (eyedrops and eyerods)
Number of subjects: 0
Study 3909958 — intervention group
Group type: EXPERIMENTAL
Intervention: ACV-IFN combination
Number of subjects: 0
Study 3909958 — intervention group
Group type: COMPARATOR
Intervention: ACV-Placebo combination
Number of subjects: 0
Study 30702372 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg·kg‐1 of caffeine
Number of subjects: 20
Study 30702372 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg·kg‐1 of caffeine
Number of subjects: 20
Study 30702372 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg·kg‐1 of caffeine
Number of subjects: 20
Study 30702372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28797202 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to smiles of joy
Number of subjects: 0
Study 28797202 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to tears of joy
Number of subjects: 0
Study 26653674 — intervention group
Group type: EXPERIMENTAL
Intervention: TM-training (12-cm slip)
Number of subjects: 36
Study 26653674 — intervention group
Group type: EXPERIMENTAL
Intervention: TM-training (18-cm slip)
Number of subjects: 36
Study 26653674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no perturbation)
Number of subjects: 36
Study 26653674 — intervention group
Group type: EXPERIMENTAL
Intervention: OG-training (overground perturbation training)
Number of subjects: 36
Study 24661791 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (HFS)
Number of subjects: 17
Study 24661791 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency stimulation (LFS)
Number of subjects: 17
Study 24661791 — intervention group
Group type: COMPARATOR
Intervention: DBS-OFF
Number of subjects: 17
Study 24330763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention (six automated voice messages for family planning support)
Number of subjects: 500
Study 24330763 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 500
Study 24330763 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention
Number of subjects: 500
Study 20535950 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0
Study 17690882 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion to maintain Hb levels >or=10 g/dl (arm 1)
Number of subjects: 87
Study 17690882 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion to maintain Hb levels >or=12 g/dl (arm 2)
Number of subjects: 87
Study 15725943 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl (saline load)
Number of subjects: 18
Study 15725943 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 18
Study 12667975 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal practitioners
Number of subjects: 0
Study 12667975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10686454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR 2.0-3.0)
Number of subjects: 4500
Study 10686454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dipyridamole (400 mg daily) plus aspirin (30-325 mg daily)
Number of subjects: 4500
Study 10686454 — intervention group
Group type: COMPARATOR
Intervention: Aspirin only
Number of subjects: 4500
Study 8672381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.5 mg
Number of subjects: 385
Study 8672381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg
Number of subjects: 385
Study 8672381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 385
Study 8672381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 1387073 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with insulin and sulfonylurea
Number of subjects: 17
Study 1387073 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy alone (control group)
Number of subjects: 17
Study 2433310 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention focusing on the development of the infant
Number of subjects: 0
Study 2433310 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention focusing on the parent-infant interaction
Number of subjects: 0
Study 2433310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 31909423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied once
Number of subjects: 60
Study 31909423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied three times
Number of subjects: 60
Study 31909423 — intervention group
Group type: EXPERIMENTAL
Intervention: Brood interruption
Number of subjects: 60
Study 31909423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied once + brood interruption
Number of subjects: 60
Study 31909423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalic Acid (OA) applied three times + brood interruption
Number of subjects: 60
Study 31909423 — intervention group
Group type: COMPARATOR
Intervention: No OA or brood interruption
Number of subjects: 60
Study 31909423 — intervention group
Group type: COMPARATOR
Intervention: Amitraz (Apivar - positive control)
Number of subjects: 60
Study 29990690 — intervention group
Group type: EXPERIMENTAL
Intervention: ReciGen®
Number of subjects: 71
Study 29990690 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif®
Number of subjects: 71
Study 29990690 — intervention group
Group type: EXPERIMENTAL
Intervention: ReciGen® or Rebif® for >24 months
Number of subjects: 71
Study 29990690 — intervention group
Group type: COMPARATOR
Intervention: ReciGen® and Rebif®
Number of subjects: 71
Study 27604335 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 70
Study 27604335 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL-148)
Number of subjects: 70
Study 25439449 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 16304
Study 25439449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16304
Study 23110676 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-factor model (pain intensity, activity interference, affective interference)
Number of subjects: 184
Study 19804593 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid (5-ALA) patch-PDT
Number of subjects: 316
Study 19804593 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 316
Study 19804593 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 316
Study 22944145 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21‐1
Number of subjects: 250
Study 22944145 — intervention group
Group type: EXPERIMENTAL
Intervention: NMP22
Number of subjects: 250
Study 22944145 — intervention group
Group type: EXPERIMENTAL
Intervention: UBC
Number of subjects: 250
Study 22944145 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP
Number of subjects: 250
Study 22944145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of markers
Number of subjects: 250
Study 16424843 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamate (n = 10)
Number of subjects: 20
Study 16424843 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n = 10)
Number of subjects: 20
Study 12856386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (mean MW = 6500 Da; 3.5% of fractions < 2000 Da)
Number of subjects: 30
Study 12856386 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin-like LMWH (mean MW = 5650 Da; 18.3% of fractions < 2000 Da)
Number of subjects: 30
Study 10212170 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (10% solution, 5 ml/kg for 30 minutes)
Number of subjects: 19
Study 10212170 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 19
Study 10212170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8588166 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain group
Number of subjects: 0
Study 8588166 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 0
Study 8588166 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline disc degeneration
Number of subjects: 0
Study 8588166 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial disc protrusion
Number of subjects: 0
Study 2575521 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (A200)
Number of subjects: 5
Study 2575521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 5
Study 2575521 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg (P40)
Number of subjects: 5
Study 30321084 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + EX
Number of subjects: 51
Study 30321084 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 51
Study 30321084 — intervention group
Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 51
Study 31124147 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm implants alone
Number of subjects: 225
Study 31124147 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm implants + OSFE
Number of subjects: 225
Study 31124147 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mm implants + OSFE
Number of subjects: 225
Study 31124147 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 225
Study 28701288 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fentanyl (33 μg kg−1 loading dose, 0.2 μg kg−1 minute−1)
Number of subjects: 8
Study 28701288 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fentanyl (102 μg kg−1 loading dose, 0.8 μg kg−1 minute−1)
Number of subjects: 8
Study 26664151 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 600 mg oral daily
Number of subjects: 53
Study 26664151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 23814841 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive prolonged drainage of a perineal wound
Number of subjects: 0
Study 21668522 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg day(-1) for adults; 2 mg kg(-1) day(-1) for children)
Number of subjects: 1061
Study 21668522 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 or 150 mg day(-1))
Number of subjects: 1061
Study 21668522 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AmB 3 mg kg(-1) day(-1))
Number of subjects: 1061
Study 21668522 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (50 mg day(-1); 70 mg loading dose)
Number of subjects: 1061
Study 21668522 — intervention group
Group type: COMPARATOR
Intervention: All drugs (Micafungin, L-AmB, Caspofungin)
Number of subjects: 1061
Study 18295615 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve‐week adherence intervention (weekly phone calls and home visit) including counseling on establishing, monitoring, and problem‐solving in maintaining a home exercise program
Number of subjects: 106
Study 18295615 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study 16932345 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-infusional consolidation chemotherapy (mini-ICE regimen)
Number of subjects: 346
Study 16932345 — intervention group
Group type: COMPARATOR
Intervention: Intravenous consolidation chemotherapy (mini-ICE regimen)
Number of subjects: 346
Study 16932345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both non-infusional and intravenous consolidation chemotherapy
Number of subjects: 346
Study 12932938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernous arterial insufficiency in men aged 50 to 59 years
Number of subjects: 158
Study 12932938 — intervention group
Group type: COMPARATOR
Intervention: No cavernous arterial insufficiency in men aged 50 to 59 years
Number of subjects: 158
Study 12932938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavernous arterial insufficiency in men aged 40 to 49 years and 60 to 69 years
Number of subjects: 158
Study 12932938 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population of men with ED
Number of subjects: 158
Study 10883562 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0
Study 9334893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily for 20 weeks)
Number of subjects: 14
Study 9334893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after withdrawal from fluoxetine)
Number of subjects: 14
Study 1492275 — intervention group
Group type: EXPERIMENTAL
Intervention: cinoxacin
Number of subjects: 150
Study 1492275 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Number of subjects: 150
Study 1492275 — intervention group
Group type: EXPERIMENTAL
Intervention: pefloxacin
Number of subjects: 150
Study 2930987 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol) for 9 months
Number of subjects: 34
Study 2930987 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Number of subjects: 34
Study 2930987 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Number of subjects: 34
Study 2930987 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose CA
Number of subjects: 34
Study 29389692 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT drop-box height group (n = 24)
Number of subjects: 73
Study 29389692 — intervention group
Group type: EXPERIMENTAL
Intervention: FIXED drop-box height group (n = 25)
Number of subjects: 73
Study 29389692 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 73
Study 26481764 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney injury molecule‐1 (KIM‐1) measured 24 h after operation
Number of subjects: 29
Study 26481764 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetyl‐glucosaminidase (NAG) measured preop and postop 24 h
Number of subjects: 29
Study 26481764 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil gelatinase‐associated lipocalin (NGAL) measured 24 h after operation
Number of subjects: 29
Study 26481764 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver‐type fatty acid binding protein (LFABP) measured preop and postop 24 h
Number of subjects: 29
Study 24682986 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia with 0.1% ropivacaine+0.1 μg/mL sufentanil (for postoperative 48 h)+injected pethidine on demand
Number of subjects: 60
Study 24682986 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral analgesia with controlled-release oxycodone (2x15 mg for the first postoperative 24 h; 2x10 mg for the second postoperative 24 h)+paracetamol and tramadol hydrochloride tablets (8x1 tablet for the postoperative 48 h) orally+injected pethidine on demand
Number of subjects: 60
Study 22819741 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative graduated compression bandage (NGCB) with median calf pressure of 62 mmHg and distal leg pressure of 50 mmHg
Number of subjects: 20
Study 22819741 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression bandage (GCB) with median calf pressure of 28 mmHg and distal leg pressure of 54 mmHg
Number of subjects: 20
Study 20455671 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualified healthcare professionals
Number of subjects: 460
Study 20455671 — intervention group
Group type: COMPARATOR
Intervention: Trainee healthcare professionals
Number of subjects: 460
Study 18541641 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day communication skills course
Number of subjects: 172
Study 18541641 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study 16398945 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with stimulation (TS)
Number of subjects: 27
Study 16398945 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground training with stimulation (OG)
Number of subjects: 27
Study 16398945 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with manual assistance (TM)
Number of subjects: 27
Study 16398945 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with robotic assistance (LR)
Number of subjects: 27
Study 16398945 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 27
Study 12097688 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-restricted diet (4.6 mg/d) during the 10-week zinc-restriction (ZR) period
Number of subjects: 8
Study 12097688 — intervention group
Group type: COMPARATOR
Intervention: Zinc supplements (9.1 mg/d) during the 5-week baseline (BL) and 5-week repletion (RP) periods
Number of subjects: 8
Study 10424318 — intervention group
Group type: EXPERIMENTAL
Intervention: digoxin 0.25 mg twice daily
Number of subjects: 12
Study 10424318 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7548447 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-rich bread with 100, 200, and 300 micrograms Se daily for 6 weeks
Number of subjects: 42
Study 7548447 — intervention group
Group type: COMPARATOR
Intervention: 400 micrograms selenomethionine daily for 15 weeks
Number of subjects: 42
Study 2125742 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil
Number of subjects: 8
Study 2125742 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 micrograms enprostil
Number of subjects: 8
Study 2125742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6998594 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of the live oral typhoid vaccine Ty21a (1 x 10(9)‐8 x 10(9) live bacteria)
Number of subjects: 32388
Study 6998594 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of placebo
Number of subjects: 32388
Study 31489717 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes health program (n=75)
Number of subjects: 146
Study 31489717 — intervention group
Group type: COMPARATOR
Intervention: Publicly available diabetes health brochure (n=71)
Number of subjects: 146
Study 31182448 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole
Number of subjects: 210
Study 31182448 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 210
Study 29143869 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 20
Study 29143869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg
Number of subjects: 20
Study 29143869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20